January 17, 2024

Aravive, Inc. to Delist from The Nasdaq Stock Market

August 02, 2023

Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

July 28, 2023

Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

July 14, 2023

Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023

June 13, 2023

Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)

June 05, 2023

Aravive To Participate in the Jefferies Global Healthcare Conference

May 25, 2023

Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023

May 16, 2023

Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

May 10, 2023

Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates

May 08, 2023

Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept

April 26, 2023

Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting

April 11, 2023

Aravive Appoints Carolina Petrini as Chief Commercial Officer

March 15, 2023

Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

February 28, 2023

Aravive Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer

February 13, 2023

Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium

January 04, 2023

Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer

November 29, 2022

Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

November 21, 2022

Aravive To Participate in Piper’s 34th Annual Healthcare Conference

November 16, 2022

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

November 10, 2022

Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

October 25, 2022

Aravive Announces Approximately $41.5 Million Private Placement Financing

October 10, 2022

Aravive Receives Third Development Milestone from 3D Medicines

September 26, 2022

Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference

September 06, 2022

Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference

August 11, 2022

Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

July 05, 2022

Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

June 03, 2022

Aravive Appoints Rudy Howard as Chief Financial Officer

May 26, 2022

Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)

May 17, 2022

Aravive to Participate in H.C. Wainwright Global Investment Conference

May 12, 2022

Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates

May 05, 2022

Aravive to Host Key Opinion Leader Symposium on May 11, 2022

April 29, 2022

Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting

April 01, 2022

Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 31, 2022

Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates

March 30, 2022

Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 22, 2022

Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer

March 07, 2022

Aravive to Participate In-Person at 34th Annual ROTH Conference

March 03, 2022

Aravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

March 02, 2022

Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

January 31, 2022

Aravive Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

January 03, 2022

Aravive Announces $10.0 Million Investment by Eshelman Ventures, LLC and Appointment of Dr. Eshelman as Executive Chairman of the Aravive Board of Directors

November 15, 2021

Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference

November 12, 2021

Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma

November 09, 2021

Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting

October 28, 2021

Aravive Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

October 01, 2021

Aravive to Present New Preliminary Data from Phase 1b Trial Evaluating AVB-500 in Clear Cell Renal Cell Carcinoma at 2021 Society for Immunotherapy of Cancer Annual Meeting

September 16, 2021

Aravive to Participate in Fireside Chat at Cantor Fitzgerald Virtual Global Healthcare Conference

September 01, 2021

Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference

August 09, 2021

Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

August 05, 2021

Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates